Trial
NCT04853043
Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Utah
Collaborators
National Cancer Institute (NCI)
Condition
Colorectal Cancer
Intervention
Cetuximab
Why stopped
PI Determination - Slow recruitment, funding concerns, poor response to treatment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-06